Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis
Open Access
- 22 May 2015
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 29 (7) , 943-950
Abstract
To compare dexamethasone (DEX) intravitreal implant effect in non-vitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis. Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology. Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12–24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P=NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P=NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P=0.025) to 12th month (P=0.013). Vitreous haze score improved in both groups since first month and showed no differences (P=0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5–6). Ocular hypertension (47.6%) was the most common adverse event. DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring.Keywords
This publication has 20 references indexed in Scilit:
- Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein OcclusionOphthalmic Surgery, Lasers and Imaging Retina, 2013
- Periocular Triamcinolone Acetonide Injections for Cystoid Macular Edema Complicating Noninfectious UveitisAmerican Journal of Ophthalmology, 2011
- Pharmacokinetics of a Sustained-Release Dexamethasone Intravitreal Implant in Vitrectomized and Nonvitrectomized EyesInvestigative Ophthalmology & Visual Science, 2011
- Clinical applications of the sustained-release dexamethasone implant for treatment of macular edemaClinical Ophthalmology, 2011
- Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitisClinical & Experimental Ophthalmology, 2009
- Impact of Macular Edema on Visual Acuity in UveitisOphthalmology, 2006
- Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International WorkshopAmerican Journal of Ophthalmology, 2005
- Long-term results of pars plana vitrectomy in the management of intermediate uveitisCurrent Opinion in Ophthalmology, 1996
- Longitudinal Data Analysis Using Generalized Linear ModelsBiometrika, 1986
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986